Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00442702
Registration number
NCT00442702
Ethics application status
Date submitted
1/03/2007
Date registered
2/03/2007
Date last updated
19/12/2011
Titles & IDs
Public title
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.
Query!
Scientific title
An Open-label, Randomized, Multi-center, Parallel Group Non-inferiority Study of Subcutaneous Injections of RO0503821 Given Once Monthly vs. Darbepoetin Alfa Given According to Local Label in Patients With Chronic Kidney Disease Who Are Not on Dialysis.
Query!
Secondary ID [1]
0
0
BH20051
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Anemia
0
0
Query!
Condition category
Condition code
Renal and Urogenital
0
0
0
0
Query!
Kidney disease
Query!
Renal and Urogenital
0
0
0
0
Query!
Other renal and urogenital disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Mircera
Treatment: Drugs - Darbepoetin alfa
Experimental: Mircera - Participants received Mircera by subcutaneous injection once every month during the dose titration (7 months) and evaluation period (2 months). The starting dose was based on the weekly dose of darbepoetin alfa administered prior to the switch to Mircera, and was either 120, 200 or 360 µg Mircera per month. The dose was then adjusted to maintain Hemoglobin levels within the defined target range and also according to the need for red blood cell transfusions (due to worsening anemia), or for toxicity related to Mircera.
Active comparator: Darbepoetin alfa - Participants continued to receive the same dose of darbepoetin alfa as before screening by subcutaneous injection once every week, once every 2 weeks or once every month as per local labeling during the dose titration (7 months) and the evaluation period (2 months).
Treatment: Drugs: Mircera
Starting dose of 120, 200 and 360 micrograms administered by subcutaneous injection once a month.
Treatment: Drugs: Darbepoetin alfa
As prescribed, subcutaneous injection once every week, once every 2 weeks or once every month as per local labeling specifications.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change in Hemoglobin (Hb) Concentration From Baseline to the Evaluation Period
Query!
Assessment method [1]
0
0
A time adjusted average baseline hemoglobin (Hb) concentration was calculated using the trapezoid rule from all available Hb measurements taken during the baseline period. The average evaluation period Hb concentration for each individual was calculated using the same method, from all their available measurements taken during the two month evaluation period. The change in Hb concentration between the baseline and evaluation periods was calculated by subtracting the baseline Hb from the evaluation period Hb. All blood samples for Hb measurements were taken prior to study drug administration.
Query!
Timepoint [1]
0
0
Baseline (measurements at Week -4, Week -2 and Day 1) and Evaluation Period (Months 8 and 9; measurements twice a month and at the final visit).
Query!
Secondary outcome [1]
0
0
Change in Hemoglobin Concentration From Baseline Over Time
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
From Baseline to 9 months; blood samples for hemoglobin measurements were taken twice a month, at each study visit.
Query!
Secondary outcome [2]
0
0
Number of Participants With Red Blood Cell (RBC) Transfusions
Query!
Assessment method [2]
0
0
Red blood cell (RBC) transfusions could be given during the treatment period in case of medical need, i.e., in severely anemic patients with recognized symptoms or signs of anemia (e.g., in patients with acute blood loss, with severe angina, or whose Hemoglobin decreased to critical levels). The number of participants who had at least one red blood cell transfusion during the entire study, during the Titration Period and during the Evaluation Period is presented. Participants who received more than one transfusion within a defined period are only counted once.
Query!
Timepoint [2]
0
0
From randomization to Month 9
Query!
Secondary outcome [3]
0
0
Participants With Adverse Events
Query!
Assessment method [3]
0
0
Adverse events were collected during the treatment period (from the first treatment dose) up to 30 days after last dose or at least until the date of last contact if the date of last contact occurred after the specified 30 day period.
Query!
Timepoint [3]
0
0
Randomization to Month 10 (final visit)
Query!
Eligibility
Key inclusion criteria
* adult patients, >=18 years of age;
* chronic kidney disease, not requiring dialysis;
* receiving darbepoetin alfa maintenance therapy for >=8 weeks before screening, and during screening/baseline period.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* overt gastrointestinal bleeding within 8 weeks before screening, or during screening/baseline period;
* transfusion of red blood cells within 8 weeks before screening, or during screening/baseline period;
* active malignant disease;
* previous treatment with Mircera.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/09/2007
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/08/2010
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
228
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
- Adelaide
Query!
Recruitment hospital [2]
0
0
- Gosford
Query!
Recruitment hospital [3]
0
0
- Lismore
Query!
Recruitment hospital [4]
0
0
- Reservoir
Query!
Recruitment hospital [5]
0
0
- Richmond
Query!
Recruitment postcode(s) [1]
0
0
SA 5000 - Adelaide
Query!
Recruitment postcode(s) [2]
0
0
2250 - Gosford
Query!
Recruitment postcode(s) [3]
0
0
2480 - Lismore
Query!
Recruitment postcode(s) [4]
0
0
3073 - Reservoir
Query!
Recruitment postcode(s) [5]
0
0
3121 - Richmond
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Georgia
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
New York
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
North Carolina
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Oregon
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Rhode Island
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Tennessee
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Virginia
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
West Virginia
Query!
Country [11]
0
0
Belgium
Query!
State/province [11]
0
0
Aalst
Query!
Country [12]
0
0
Belgium
Query!
State/province [12]
0
0
Roeselare
Query!
Country [13]
0
0
Canada
Query!
State/province [13]
0
0
Alberta
Query!
Country [14]
0
0
Canada
Query!
State/province [14]
0
0
Newfoundland and Labrador
Query!
Country [15]
0
0
Canada
Query!
State/province [15]
0
0
Ontario
Query!
Country [16]
0
0
Canada
Query!
State/province [16]
0
0
Quebec
Query!
Country [17]
0
0
Czech Republic
Query!
State/province [17]
0
0
Marianske Lazne
Query!
Country [18]
0
0
Czech Republic
Query!
State/province [18]
0
0
Praha 2
Query!
Country [19]
0
0
Czech Republic
Query!
State/province [19]
0
0
Praha 4
Query!
Country [20]
0
0
Czech Republic
Query!
State/province [20]
0
0
Praha
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
La Tronche
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Nantes
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Orleans
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Paris
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Rennes
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
St Priest En Jarez
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Strasbourg
Query!
Country [28]
0
0
Germany
Query!
State/province [28]
0
0
Bad Hersfeld
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Bad König
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Berlin
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Bonn
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Coburg
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Demmin
Query!
Country [34]
0
0
Germany
Query!
State/province [34]
0
0
Dortmund
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
München
Query!
Country [36]
0
0
Hungary
Query!
State/province [36]
0
0
Baja
Query!
Country [37]
0
0
Hungary
Query!
State/province [37]
0
0
Budapest
Query!
Country [38]
0
0
Hungary
Query!
State/province [38]
0
0
Esztergom
Query!
Country [39]
0
0
Hungary
Query!
State/province [39]
0
0
Hodmezovasarhely
Query!
Country [40]
0
0
Hungary
Query!
State/province [40]
0
0
Kalocsa
Query!
Country [41]
0
0
Hungary
Query!
State/province [41]
0
0
Kecskemet
Query!
Country [42]
0
0
Hungary
Query!
State/province [42]
0
0
Szigetvar
Query!
Country [43]
0
0
Hungary
Query!
State/province [43]
0
0
VAC
Query!
Country [44]
0
0
Israel
Query!
State/province [44]
0
0
Hadera
Query!
Country [45]
0
0
Israel
Query!
State/province [45]
0
0
Jerusalem
Query!
Country [46]
0
0
Israel
Query!
State/province [46]
0
0
Kfar Saba
Query!
Country [47]
0
0
Israel
Query!
State/province [47]
0
0
Nahariya
Query!
Country [48]
0
0
Israel
Query!
State/province [48]
0
0
Rehovot
Query!
Country [49]
0
0
Italy
Query!
State/province [49]
0
0
Brescia
Query!
Country [50]
0
0
Italy
Query!
State/province [50]
0
0
Chieti
Query!
Country [51]
0
0
Italy
Query!
State/province [51]
0
0
Ferrara
Query!
Country [52]
0
0
Italy
Query!
State/province [52]
0
0
Genova
Query!
Country [53]
0
0
Italy
Query!
State/province [53]
0
0
La Spezia
Query!
Country [54]
0
0
Italy
Query!
State/province [54]
0
0
Lecco
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
Lodi
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
Palermo
Query!
Country [57]
0
0
Italy
Query!
State/province [57]
0
0
Pavia
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
Prato
Query!
Country [59]
0
0
Italy
Query!
State/province [59]
0
0
Roma
Query!
Country [60]
0
0
Italy
Query!
State/province [60]
0
0
S Fermo Della Battaglia
Query!
Country [61]
0
0
Poland
Query!
State/province [61]
0
0
Gdansk
Query!
Country [62]
0
0
Poland
Query!
State/province [62]
0
0
Katowice
Query!
Country [63]
0
0
Poland
Query!
State/province [63]
0
0
Lodz
Query!
Country [64]
0
0
Poland
Query!
State/province [64]
0
0
Radom
Query!
Country [65]
0
0
Poland
Query!
State/province [65]
0
0
Rzeszow
Query!
Country [66]
0
0
Poland
Query!
State/province [66]
0
0
Sieradz
Query!
Country [67]
0
0
Poland
Query!
State/province [67]
0
0
Szczecin
Query!
Country [68]
0
0
Poland
Query!
State/province [68]
0
0
Warszawa
Query!
Country [69]
0
0
Spain
Query!
State/province [69]
0
0
Barcelona
Query!
Country [70]
0
0
Spain
Query!
State/province [70]
0
0
Ciudad Real
Query!
Country [71]
0
0
Spain
Query!
State/province [71]
0
0
Hospitalet de Llobregat
Query!
Country [72]
0
0
Spain
Query!
State/province [72]
0
0
La Coruna
Query!
Country [73]
0
0
Spain
Query!
State/province [73]
0
0
Lerida
Query!
Country [74]
0
0
Spain
Query!
State/province [74]
0
0
Madrid
Query!
Country [75]
0
0
Spain
Query!
State/province [75]
0
0
Málaga
Query!
Country [76]
0
0
Spain
Query!
State/province [76]
0
0
Partida La Ceñuela. Torreviej
Query!
Country [77]
0
0
United Kingdom
Query!
State/province [77]
0
0
Belfast
Query!
Country [78]
0
0
United Kingdom
Query!
State/province [78]
0
0
Birmingham
Query!
Country [79]
0
0
United Kingdom
Query!
State/province [79]
0
0
Bradford
Query!
Country [80]
0
0
United Kingdom
Query!
State/province [80]
0
0
Exeter
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This 2 arm study will compare the efficacy and safety of Mircera and darbepoetin alfa in the treatment of anemia in patients with chronic kidney disease who are not on dialysis and who are receiving subcutaneous darbepoetin alfa maintenance therapy. Patients will be randomized either to remain on darbepoetin alfa therapy as per local label, or to switch to monthly subcutaneous Mircera, at a starting dose of 120, 200 or 360 micrograms, depending on the weekly dose of darbepoetin alfa administered prior to the first dose of Mircera. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00442702
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT00442702
Download to PDF